SCHEMBL5518836

SCHEMBL5518836

C[Si](C)(C)CCOCn1nc(-c2nc3ccccc3n2COCC[Si](C)(C)C)c2cc(-c3ccccc3)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.44
HSD17B10 Q99714 6/20 0.44
TP53 P04637 7/20 0.41
ALDH1A1 P00352 6/20 0.41
NPC1 O15118 3/20 0.41
HPGD P15428 3/20 0.41
RAB9A P51151 2/20 0.41
MAPK1 P28482 1/20 0.41
MAPT P10636 5/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 2/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
RECQL P46063 1/20 0.38
PDE6D O43924 1/20 0.36
ALDH2 P05091 1/20 0.36
ALDH3A1 P30838 1/20 0.36
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
GAA P10253 1/20 0.35
PTGER4 P35408 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5522745 0.91 KDM4E (0.44) KDM4EHSD17B10TP53ALDH1A1NPC1
SCHEMBL3538698 0.88 HSD17B10 (0.43) KDM4EHSD17B10TP53ALDH1A1NPC1
SCHEMBL5518847 0.88 KDM4E (0.39) KDM4EHSD17B10TP53ALDH1A1NPC1
SCHEMBL5510647 0.88 KDM4E (0.38) KDM4EHSD17B10TP53ALDH1A1NPC1
SCHEMBL5249126 0.86 KDM4E (0.39) KDM4EHSD17B10TP53ALDH1A1NPC1
SCHEMBL31172421 0.86 NPC1 (0.44) NPC1PTGER4
SCHEMBL31172384 0.84 NPC1 (0.42) KDM4ENPC1MAPTPTGER4
SCHEMBL5253124 0.82 KDM4E (0.39) KDM4EHSD17B10TP53ALDH1A1NPC1
SCHEMBL3536514 0.80 DRD3 (0.44) KDM4EHSD17B10TP53ALDH1A1NPC1
SCHEMBL14493396 0.79 MKNK1 (0.41) KDM4EHSD17B10ALDH1A1NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7232912-B2 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS, INC. (US) 2007-06-19 US disclosed
US-7232912-B2 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS, INC. (US) 2007-06-19 US disclosed
US-7232912-B2 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS, INC. (US) 2007-06-19 US disclosed
US-20060111322-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS, INC. 2006-05-25 US disclosed
US-20050239855-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS, INC. 2005-10-27 US disclosed
US-6919461-B2 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS, INC. (US) 2005-07-19 US disclosed
US-20030139463-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation REICH SIEGFRIED HEINZ (US) 2003-07-24 US disclosed
US-6555539-B2 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis AGOURON PHARMACEUTICALS 2003-04-29 US disclosed
US-20020161022-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation AGOURON PHARMACEUTICALS 2002-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239855-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation CDK3, MKI67, ROCK1 KDM4E 2501/4885HSD17B10 3499/4885TP53 134/4885
US-20020161022-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation CDK3, MKI67, ROCK1 KDM4E 2501/4885HSD17B10 3499/4885TP53 134/4885
US-20030139463-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation CDK3, MKI67, ROCK1 KDM4E 2501/4885HSD17B10 3499/4885TP53 134/4885
US-20060111322-A1 Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation MKI67, CCNI, CDK3 KDM4E 2084/4885HSD17B10 1552/4885TP53 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.